While somatic mutations in ANDR have been strongly linked with lack of response to hormone therapy and/or agonist response to anti-androgens in prostate cancer, it is only recently that the importance of ESR1 mutations in BC has been reported (reviewed by Jeselsohn et al.7). This evidence concerns the gene ESR1 and prostate carcinoma.